

# Comparative 3 Year ACTIS™ Stem data

**Actis™**  
TOTAL HIP SYSTEM


Survival analysis for all-cause revision following primary total hip arthroplasty with a medial collared, triple-tapered primary hip stem versus other implants in real-world settings.

**Chitnis A, Mantel J, Ruppenkamp J, Bourcet A, Holy C**  
Current Medical Research Opinion. 2020 Sep 22:1-7.

- A retrospective cohort study identified 1,213 patients who received the ACTIS™ Total Hip. This group was compared to 6,916 patients who received other THA implants.
- Data was drawn from the Mercy Healthcare Systems Orthopedics Database, a large US based multi-state database.
- Kaplan-Meier survival curves were generated, and a multivariable Cox proportional hazard model was used to compare the relative risk of revision.

## 57% lower risk of revisions

Adjusted Hazard Ratio 0.43 ((0.19-0.97)  $p=0.042$ )



**57% Reduced Risk of Revision when  
Compared to Other THA Implants**

Please refer to the instructions for use for a complete list of indications, contraindications, warnings and precautions.

 **DePuy Synthes**

PART OF THE **Johnson & Johnson** FAMILY OF COMPANIES

Johnson & Johnson Medical Limited, Baird House, 4 Lower Gilmore Bank, Edinburgh, EH3 9QP, United Kingdom.  
Incorporated and registered in Scotland under company number SC132162.

[www.jnjmedicaldevices.com](http://www.jnjmedicaldevices.com)

© DePuy Synthes 2020. All Rights Reserved.  
155950-201015 DSUS/EMEA